BioNTech SE (22UA) Stock Price & Analysis
22UA Stock Chart & Stats
- Day’s Range
- EUR 78.75 - EUR 80.75
- 52-Week Range
- EUR 68.30 - EUR 105.70
- Previous Close
- EUR 79.15
- Volume
- N/A
- Average Volume (3M)
- 25.67K
- Market Cap
- EUR 19.83B
- Enterprise Value
- EUR 6.84B
- Total Cash (Recent Filing)
- EUR 9.74B
- Total Debt (Recent Filing)
- EUR 315.97M
- Price to Earnings (P/E)
- ―
- Beta
- 0.86
- Next Earnings
- Nov 03, 2026 (Est.)
- EPS Estimate
- 0.67
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet
Very low leverage and substantial liquidity give BioNTech significant flexibility to fund clinical development, absorb ongoing losses, and pursue strategic opportunities. This financial capacity reduces dependence on near-term product revenue and supports investment through the oncology pipeline’s longer approval timelines.
Late-stage Oncology Pipeline
Multiple late-stage oncology programs create several potential sources of future product revenue beyond COVID-19 vaccines. Advancement of LCD into Phase III, alongside broad pivotal activity across tumor types, indicates meaningful development scale and preserves the possibility of pipeline diversification.
Strategic Combination Expansion
The Gilead collaboration expands pumitamig into a contemporary combination strategy and gives BioNTech access to an established ADC partner for a large unmet-need setting. The partnership can broaden clinical applicability and strengthen the asset’s potential role as a combination backbone.
Bears Say
COVID Revenue Dependence
BioNTech’s commercial performance remains heavily exposed to the maturing COVID-19 vaccine market, making revenue vulnerable as demand shifts from pandemic procurement to seasonal use. This dependence creates a difficult bridge until oncology programs generate recurring commercial revenue.
Persistent Operating Losses
Planned operating spending substantially exceeds guided revenue, while the company is already reporting sizable losses. Continued investment is strategically necessary, but the mismatch can pressure profitability and cash conversion if clinical progress does not translate into approvals or partner payments.
Clinical Execution Setbacks
Important setbacks in mRNA oncology show that promising platform science has not yet translated consistently into clinical benefit. Failed or halted studies can redirect resources, delay portfolio validation, and increase the burden on fewer remaining programs to support BioNTech’s long-term transition.
BioNTech SE News
22UA FAQ
What was BioNTech SE’s price range in the past 12 months?
What is BioNTech SE’s market cap?
When is BioNTech SE’s upcoming earnings report date?
How were BioNTech SE’s earnings last quarter?
Is BioNTech SE overvalued?
Does BioNTech SE pay dividends?
What is BioNTech SE’s EPS estimate?
How many shares outstanding does BioNTech SE have?
What happened to BioNTech SE’s price movement after its last earnings report?
Which hedge fund is a major shareholder of BioNTech SE?
What is the TipRanks Smart Score and how is it calculated?
BioNTech SE Stock Smart Score
Company Description
BioNTech SE
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ugur Sahin
- Employees
- 7,807
- Website
- www.biontech.com/de/de/home.html
- Address
- An der Goldgrube 12, Mainz, RP, 55131, DE
BioNTech SE (22UA) Earnings & Revenues
22UA Company Deck
22UA Earnings Call
Earnings Call SentimentNeutral
The call balances meaningful near‑term financial headwinds (sharp Q2 revenue decline, guidance reduction, increased SG&A and some timeline pushes) against substantial clinical and strategic progress: multiple encouraging Phase II signals (pumitamig, gotistobart), initiation of a Phase III for LCD, continued advancement of mRNA oncology programs, a strong cash position (EUR 16.6B) and active capital return. The pipeline momentum and capital strength mitigate short‑term revenue weakness, but the quarter highlights both execution progress and clear near‑term commercial challenges.
View all DE:22UA earnings summaries22UA Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 5 | 12 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 2 | 0 | 10 |
